Abstract
The notes provided in this article relate to two components of the development of vaccines against schistosomiasis: (1) The characteristics of schistosome infections (eg. features of the schistosome life cycle), and the parasite itself, that have implications for vaccination strategies; (2) The characteristics of the biopharmaceutical industry that have implications for product development. As will be seen, these two topic areas are not vastly disparate.
schistosomiasis; vaccines; life cycle; immunopathology; pharmaceutical industry
Opportunities and constraints in schistosomiasis vaccine development: infection characteristics and industry realities
Graham F. Mitchell1
CSL Limited, R&D Division, Parkville, Australia
The notes provided in this article relate to two components of the development of vaccines against schistosomiasis: (1) The characteristics of schistosome infections (eg. features of the schistosome life cycle), and the parasite itself, that have implications for vaccination strategies; (2) The characteristics of the biopharmaceutical industry that have implications for product development. As will be seen, these two topic areas are not vastly disparate.
Full text available only in PDF format.
Texto completo disponível apenas em PDF.
Publication Dates
-
Publication in this collection
01 June 2009 -
Date of issue
Apr 1995
